Patents by Inventor Michael Crimmins

Michael Crimmins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE
    Publication number: 20080076735
    Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.
    Type: Application
    Filed: December 4, 2007
    Publication date: March 27, 2008
    Inventors: John Lampe, Robert Plourde, Jin She, Jason Vittitow, Paul Watson, Michael Crimmins, David Slade
  • Cytoskeletal active compounds, compositions and use
    Publication number: 20060217427
    Abstract: The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.
    Type: Application
    Filed: March 23, 2006
    Publication date: September 28, 2006
    Inventors: John Lampe, Robert Plourde, Jin She, Jason Vittitow, Paul Watson, Michael Crimmins, David Slade